Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | protein arginine methyltransferase 8 | References | |
Homo sapiens | protein arginine methyltransferase 6 | References | |
Homo sapiens | coactivator-associated arginine methyltransferase 1 | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | histone arginine methyltransferase PRMT4/CARM1 | protein arginine methyltransferase 8 | 385 aa | 345 aa | 33.9 % |
Plasmodium falciparum | histone-arginine methyltransferase CARM1, putative | protein arginine methyltransferase 6 | 375 aa | 353 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | protein arginine N-methyltransferase, putative | 0.0047 | 0 | 0.5 |
Trypanosoma cruzi | arginine N-methyltransferase, putative | 0.0071 | 0.1933 | 0.5 |
Plasmodium vivax | protein arginine N-methyltransferase 1, putative | 0.0047 | 0 | 0.5 |
Echinococcus granulosus | histone arginine methyltransferase CARMER | 0.0175 | 1 | 1 |
Plasmodium falciparum | protein arginine N-methyltransferase 1 | 0.0047 | 0 | 0.5 |
Entamoeba histolytica | arginine N-methyltransferase protein, putative | 0.0071 | 0.1933 | 0.5 |
Loa Loa (eye worm) | Carm1-pending protein | 0.0175 | 1 | 1 |
Toxoplasma gondii | histone arginine methyltransferase PRMT4/CARM1 | 0.0175 | 1 | 1 |
Onchocerca volvulus | 0.014 | 0.7296 | 0.5 | |
Trypanosoma cruzi | arginine N-methyltransferase, putative | 0.0071 | 0.1933 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0071 | 0.1933 | 0.5 |
Schistosoma mansoni | protein arginine n-methyltransferase | 0.0175 | 1 | 1 |
Echinococcus multilocularis | histone arginine methyltransferase CARMER | 0.0175 | 1 | 1 |
Trypanosoma brucei | Protein arginine N-methyltransferase 1 catalytic subunit | 0.0071 | 0.1933 | 0.5 |
Trichomonas vaginalis | protein arginine N-methyltransferase, putative | 0.0047 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | Inhibition of human PRMT7 using 24 residues of biotin labelled histone4 substrate and tritiated 3H-S-adenosylmethionine by scintillation proximity assay | ChEMBL. | 26824386 | |
IC50 (binding) | Inhibition of human PRMT5 using 24 residues of biotin labelled histone4 substrate and tritiated 3H-S-adenosylmethionine by scintillation proximity assay | ChEMBL. | 26824386 | |
IC50 (binding) | = 0.2 uM | Inhibition of CARM1 (unknown origin) using 24 residues of biotin labelled histone4 substrate and tritiated 3H-S-adenosylmethionine by scintillation proximity assay | ChEMBL. | 26824386 |
IC50 (binding) | = 0.2 uM | Inhibition of human PRMT4 using 24 residues of biotin labelled histone4 substrate and tritiated 3H-S-adenosylmethionine by scintillation proximity assay | ChEMBL. | 26824386 |
IC50 (binding) | = 2.1 uM | Inhibition of N-terminal hexa-His tagged human PRMT6 expressed in Sf9 cells using 24 residues of biotin labelled histone4 substrate and tritiated 3H-S-adenosylmethionine by scintillation proximity assay | ChEMBL. | 26824386 |
IC50 (binding) | = 15 uM | Inhibition of human PRMT8 using 24 residues of biotin labelled histone4 substrate and tritiated 3H-S-adenosylmethionine by scintillation proximity assay | ChEMBL. | 26824386 |
IC50 (binding) | = 48 uM | Inhibition of human PRMT1 using 24 residues of biotin labelled histone4 substrate and tritiated 3H-S-adenosylmethionine by scintillation proximity assay | ChEMBL. | 26824386 |
IC50 (binding) | > 500 uM | Inhibition of human PRMT3 using 24 residues of biotin labelled histone4 substrate and tritiated 3H-S-adenosylmethionine by scintillation proximity assay | ChEMBL. | 26824386 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.